Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis.
The Symptom Inventory Disability-Specific Short Forms for Multiple Sclerosis: Reliability and Factor Structure.
Recent Gains in Clinical Multiple Sclerosis Research Review.
Novartis updates US label on Gilenya® following discussions with the FDA
Distinctive structural and functional MRI footprint for cognitive dysfunction in pediatric MS?
Immunology: A tolerant approach.
The benefits of exercise training in multiple sclerosis.
Contribution of imaging to the diagnosis of optic neuropathies.
Discovery of peptoid ligands for anti-aquaporin 4 antibodies.
Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy.
Eosinophilic Fasciitis Occurring under Treatment with Natalizumab for Multiple Sclerosis.
Insight into the role of CRMP2 (collapsin response mediator protein 2) in T lymphocyte migration: The particular context of virus infection.
Anti-integrin therapy for multiple sclerosis.
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis.
Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function.
Quantitative proton density mapping: correcting the receiver sensitivity bias via pseudo proton densities.
Prevalence of dysphagia in multiple sclerosis: a systematic review and meta-analysis.
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients.
Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis.
Fampridine – Benefit assessment according to § 35a Social Code Book V
Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies.
Overview of treatment options in multiple sclerosis.
Glycerol rhizotomy and radiofrequency thermocoagulation for trigeminal neuralgia in multiple sclerosis.
Pain Research Forum: application of scientific social media frameworks in neuroscience.
Pages
« first
‹ previous
…
176
177
178
179
180
181
182
183
184
…
next ›
last »